Related Experiment Video
Updated: Sep 19, 2025
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Exploring the PREVENT HF score and myocardial function among persons with HIV
Allie R Walpert1, Mansi Gupta1, Carolyn N Dunderdale1
1Metabolism Unit.
Insights
The AHA PREVENT HF score correlates with cardiac magnetic resonance imaging findings in people with HIV (PWH) who have subclinical myocardial dysfunction. This suggests the score may help identify early heart disease risks in PWH.
Area of Science:
- Cardiology
- Infectious Diseases
- Medical Imaging
Background:
- People with HIV (PWH) are at increased risk for myocardial structural changes, potentially leading to heart failure with preserved ejection fraction (HFpEF).
- Early detection of subclinical myocardial dysfunction is crucial for managing cardiovascular disease (CVD) risk in PWH.
- The AHA PREVENT HF risk score is a tool for predicting cardiovascular events, but its utility in PWH with subclinical disease requires investigation.
Purpose of the Study:
- To explore the association between the AHA PREVENT HF risk score and cardiac magnetic resonance (CMR) imaging findings in people with HIV (PWH).
- To assess the correlation of the PREVENT HF score with indicators of subclinical myocardial dysfunction and inflammation in PWH.
Main Methods:
- A cross-sectional study involving 37 PWH on antiretroviral therapy (ART), aged 40-65, without known CVD.
- Participants underwent cardiac magnetic resonance (CMR) imaging.
- The AHA PREVENT HF risk score was calculated and correlated with CMR-derived measures including left atrial volume index (LAVI), global longitudinal strain (GLS), left ventricular mass index (LVMI), extracellular volume (ECV), and T1 relaxation time.
Main Results:
- The PREVENT HF score showed significant correlations with LAVI (ρ=0.35, P=0.04), T1 relaxation time (ρ=0.35, P=0.04), interleukin-6 (IL-6) (ρ=0.36, P=0.03), and NT-proBNP (ρ=0.42, P=0.01).
- Higher risk scores were observed in individuals meeting clinical cutoffs for LAVI (>34 ml/m²) and T1 relaxation time (≥1250 ms).
- Optimal cutoffs for the PREVENT HF score were identified for predicting elevated LAVI (2.5, AUROC 0.769) and T1 relaxation time (3.6, AUROC 0.727).
Conclusions:
- The AHA PREVENT HF score is associated with indicators of altered myocardial structure and inflammation in asymptomatic PWH with subclinical disease.
- These findings suggest the potential utility of the PREVENT HF score in assessing radiographic findings related to cardiac health in PWH.
- Further research is needed to validate the PREVENT HF score as a predictive tool for cardiovascular outcomes in the PWH population.
Objective:
Persons with HIV (PWH) are at risk for myocardial structural changes, which can progress to diastolic dysfunction and heart failure with preserved ejection fraction (HFpEF). We explored the AHA PREVENT HF (Predicting Risk of cardiovascular disease EVENTs for Heart Failure) risk score in relation to cardiac magnetic resonance (CMR) imaging.
Design:
This cross-sectional study included 37 PWH on ART, ages 40-65, without known cardiovascular disease (CVD) who underwent CMR.
Methods:
The risk score was assessed using the AHA PREVENT HF calculator. Scores were correlated to variables on CMR that are known indicators of subclinical myocardial dysfunction [left atrial volume index (LAVI), global longitudinal strain (GLS), and left ventricular mass index (LVMI)] and inflammation [extracellular volume (ECV) and longitudinal relaxation (T1)].
Results:
PWH were age 55 (6) years [mean (SD)], predominantly male (76%) and white (57%) with BMI in the obese (≥30 kg/m 2 ) range: 31 (5) kg/m 2 . Median PREVENT HF score was 2.6 (1.4, 4.1)% [median (25th, 75th)]. The PREVENT HF score correlated to LAVI ( ρ = 0.35, P = 0.04), T1 ( ρ = 0.35, P = 0.04), interleukin (IL)-6 ( ρ = 0.36, P = 0.03) and NT-proBNP ( ρ = 0.42, P = 0.01). Risk scores were higher for those meeting clinical cutoffs LAVI >34 ml/m 2 and T1 ≥1250 ms. For predicting LAVI >34 ml/m 2 , a PREVENT HF score of 2.5 was the optimal cutoff [sensitivity 85%, specificity 65%, AUROC 0.769 ( P < 0.05)]. In predicting T1 ≥1250 ms, a PREVENT HF score of 3.6 was the optimal cutoff [71% sensitivity, 95% specificity, AUROC 0.727 ( P < 0.05)].
Conclusion:
The PREVENT HF score related to indices of altered myocardial structure and inflammation among asymptomatic PWH with subclinical disease. These data begin to inform us about the utility of PREVENT HF score using radiographic findings, though more studies are needed among PWH to validate its use as a prediction tool.
Clinical Trials Registration:
NCT02740179.
More Related Videos
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:27Heart Failure I: Introduction
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:26Coronary Artery Disease IV: Preventive Measures
01:17Pathophysiology of Heart Failure
01:29Heart Failure II: Pathophysiology